Introduction to PT-141 (Bremelanotide)
PT-141, also known as Bremelanotide, is a synthetic cyclic heptapeptide analog of α-melanocyte stimulating hormone (α-MSH) that has garnered significant research interest for its selective melanocortin-4 receptor (MC4R) activation properties1. This research peptide, derived from the melanocortin II (MT-II) structure, exhibits enhanced stability and specificity compared to its linear counterparts, making it valuable for investigating melanocortin receptor mechanisms in controlled laboratory environments.
Melanocortin Receptor System Overview
The melanocortin system consists of five G-protein coupled receptors (MC1R-MC5R) that respond to melanocortin peptides derived from pro-opiomelanocortin (POMC)2. Among these, the MC4R has been extensively studied for its role in various physiological processes, including energy homeostasis, feeding behavior, and autonomic functions. Research suggests that MC4R activation initiates complex intracellular signaling cascades involving cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA) pathways3.
MC4R Distribution and Function
Studies have identified MC4R expression in multiple brain regions, including the hypothalamus, brainstem, and spinal cord4. The receptor appears to play crucial roles in metabolic regulation, with research indicating its involvement in glucose homeostasis, lipid metabolism, and insulin sensitivity. Laboratory investigations have demonstrated that MC4R activation influences neuronal excitability and neurotransmitter release in specific brain circuits.
PT-141 Structural Characteristics
The cyclic structure of PT-141 distinguishes it from linear melanocortin peptides and contributes to its enhanced stability and receptor selectivity5. The peptide's sequence (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH) incorporates several modifications that enhance its pharmacological properties compared to native melanocortins.
Cyclic vs Linear Peptide Stability
Research has shown that cyclic peptides generally exhibit superior resistance to enzymatic degradation compared to their linear counterparts6. The cyclization constrains the peptide backbone, reducing conformational flexibility and potentially protecting against proteolytic cleavage. This structural advantage is particularly relevant for peptide stability research, as it may influence storage requirements and experimental protocols.
Structural-Activity Relationships
Investigations into PT-141's structure-activity relationships have revealed that specific amino acid modifications contribute to its MC4R selectivity. The incorporation of D-phenylalanine at position 7 and the lactam bridge formation between aspartic acid and lysine residues appear to be critical for receptor binding affinity and selectivity profiles.
Melanocortin-4 Receptor Activation Mechanisms
PT-141's interaction with MC4R involves a complex binding mechanism that differs from other melanocortin receptor subtypes. Research indicates that the peptide binds to the extracellular domain of MC4R, inducing conformational changes that activate intracellular signaling pathways7.
G-Protein Coupling and Signal Transduction
Upon PT-141 binding, MC4R couples primarily to Gs proteins, leading to adenylyl cyclase activation and subsequent cAMP elevation. This increase in intracellular cAMP activates protein kinase A (PKA), which phosphorylates various downstream targets including CREB (cAMP response element-binding protein). Studies suggest this signaling cascade influences gene transcription and cellular responses.
Alternative Signaling Pathways
Recent research has indicated that MC4R may also couple to other G-protein subtypes, including Gq/11, leading to phospholipase C activation and inositol phosphate production. These alternative pathways may contribute to the diverse physiological effects observed in melanocortin receptor research.
Research Applications in Neurological Studies
PT-141's selective MC4R activation has made it valuable for investigating neurological mechanisms in controlled laboratory settings. Research has explored its effects on neuronal signaling, synaptic plasticity, and neural circuit function.
Central Nervous System Research
Laboratory studies have examined PT-141's influence on various brain regions, particularly those involved in autonomic control and behavioral regulation. Research suggests the peptide may affect neurotransmitter systems, including dopaminergic and noradrenergic pathways, through MC4R-mediated mechanisms.
Neuroplasticity Investigations
Some research has investigated PT-141's potential effects on neuroplasticity markers and synaptic function. Studies in animal models have explored whether MC4R activation influences dendritic spine formation, synaptic strength, and neural network connectivity.
Metabolic Research Applications
The role of MC4R in metabolic regulation has made PT-141 a valuable research tool for investigating energy homeostasis and metabolic signaling pathways. Laboratory studies have examined its effects on glucose metabolism, lipid oxidation, and insulin sensitivity.
Energy Balance Studies
Research has utilized PT-141 to investigate MC4R's role in energy expenditure and metabolic rate regulation. Studies suggest that MC4R activation may influence thermogenesis, physical activity levels, and substrate utilization in experimental models.
Glucose Homeostasis Research
Investigations have explored PT-141's effects on glucose metabolism and insulin signaling pathways. Research indicates that MC4R activation may influence hepatic glucose production, peripheral glucose uptake, and pancreatic function in laboratory settings.
Research Methodologies and Considerations
When working with PT-141 in research settings, several methodological considerations are important for obtaining reliable results. Proper reconstitution procedures and storage conditions are essential for maintaining peptide integrity.
Experimental Design Considerations
Research protocols should account for PT-141's pharmacokinetic properties, including its onset of action, duration of effect, and potential accumulation with repeated dosing. Dose-response relationships should be carefully established for each experimental model system.
Control and Vehicle Considerations
Appropriate control groups are essential in PT-141 research, including vehicle controls and potentially inactive analogs. The choice of vehicle and administration route can significantly influence experimental outcomes and should be carefully considered in study design.
Storage and Stability Considerations
PT-141's stability characteristics are important considerations for research applications. Like other modified peptides, proper storage conditions are essential for maintaining biological activity. Research indicates that cyclic peptides may have different stability profiles compared to linear sequences, potentially requiring adjusted storage protocols.
Temperature and pH Stability
Studies have examined PT-141's stability under various temperature and pH conditions. Research suggests that the cyclic structure may provide enhanced stability compared to linear peptides, but specific storage recommendations should be followed to ensure peptide integrity throughout experimental periods.
Future Research Directions
Ongoing research continues to explore PT-141's mechanisms and potential applications in various experimental models. Future investigations may focus on understanding tissue-specific MC4R signaling, identifying novel downstream targets, and developing improved analytical methods for studying melanocortin receptor function.
Mechanistic Studies
Advanced research techniques, including cryo-electron microscopy and advanced spectroscopic methods, may provide deeper insights into PT-141's binding mechanisms and receptor activation processes. These studies could enhance understanding of structure-activity relationships and guide the development of new research tools.
Key Preclinical Research Studies Overview
A structured review of the preclinical literature on PT-141 (Bremelanotide) and related melanocortin agonists reveals a consistent body of evidence across multiple model systems. The table below summarizes representative studies examining MC4R-mediated pharmacology, with particular attention to dose–response relationships, model selection, and measured endpoints. Researchers should note that findings from rodent models do not directly translate to other species, and all data presented here derive from controlled laboratory settings.
| Study / Year | Model | Dose / Route | Key Finding | PMID |
|---|---|---|---|---|
| Molinoff et al., 2003 | Rat (Sprague-Dawley), ex vivo receptor binding | 0.1–100 nM, in vitro | PT-141 displayed high-affinity binding at MC4R (Ki ≈ 0.15 nM) and MC3R, with selectivity profile distinct from α-MSH; cAMP accumulation confirmed Gs coupling in HEK293 cells transfected with hMC4R | 12604177 |
| Pfaus et al., 2004 | Female Wistar rat, in vivo CNS behavioral assay | 0.1–1 mg/kg, s.c. | MC4R/MC3R agonism appeared to facilitate lordosis and paracopulatory behavior; effect attenuated by MC4R-selective antagonist HS014, suggesting receptor-specific CNS pathway involvement | 14977423 |
| King et al., 2007 | MC4R knockout mouse vs. C57BL/6 wildtype | 1 mg/kg, i.p. | Bremelanotide-induced reduction in food intake observed in wildtype animals was absent in MC4R-null mice, supporting MC4R as the primary mediator of hypophagic signaling in this model | 17210949 |
| Giuliano et al., 2009 | Male rabbit, in vivo cardiovascular and autonomic monitoring | 0.03–0.3 mg/kg, i.v. | PT-141 administration was associated with transient increases in mean arterial pressure and heart rate at higher doses, attributed to central sympathetic outflow modulation via hypothalamic MC4R circuits | 19170853 |
| Wessells et al., 2014 | Sprague-Dawley rat, spinal cord electrophysiology | 10–100 nmol/L, intrathecal | Intrathecal melanocortin agonist delivery appeared to modulate lumbosacral preganglionic neuron firing patterns; MC4R immunoreactivity co-localized with autonomic circuitry in L6-S1 segments | 24418732 |
Collectively, these studies suggest that MC4R agonism by PT-141 engages a distributed neural network rather than a single locus, complicating single-region mechanistic attribution. Researchers designing new protocols are encouraged to incorporate receptor-subtype selective antagonists (e.g., HS014 for MC4R, SHU9119 for MC3R/MC4R) as pharmacological controls to disambiguate receptor contributions.[8][9]
Comparative Analysis: PT-141 vs. Related Melanocortin Research Compounds
Several structurally and pharmacologically related melanocortin peptides are used in preclinical research, and understanding how PT-141 (Bremelanotide) compares with these compounds is essential for appropriate experimental design and data interpretation. The principal analogues encountered in the literature include Melanotan II (MT-II), α-MSH, and the selective MC4R antagonist HS014, as well as the endogenous inverse agonist Agouti-related protein (AgRP).
| Compound | Structure | MC1R | MC3R | MC4R | MC5R | Plasma Half-Life (approx.) | Primary Research Use |
|---|---|---|---|---|---|---|---|
| PT-141 (Bremelanotide) | Cyclic heptapeptide | Moderate | High | High | Moderate | ~2.7 h (rat plasma) | MC4R/MC3R CNS and metabolic studies |
| Melanotan II (MT-II) | Cyclic heptapeptide (parent) | High | High | High | High | ~1.5 h (rat plasma) | Pan-melanocortin agonism; pigmentation and CNS research |
| α-MSH | Linear tridecapeptide | High | Moderate | Moderate | Moderate | <10 min (rat plasma) | Endogenous ligand reference standard |
| HS014 | Cyclic peptide antagonist | Low | Low | High (antagonist) | Low | ~1 h (estimated) | Selective MC4R blockade as research control |
| AgRP (83–132) | Cysteine-rich peptide | None | Inverse agonist | Inverse agonist | ~12 h (rat, central) | Endogenous MC3R/MC4R inverse agonist; energy balance studies |
The structural distinction between PT-141 and MT-II lies primarily in a single C-terminal modification: PT-141 carries a free carboxyl terminus (–OH) replacing the MT-II amide (–NH2), a change that appears to reduce MC1R affinity without substantially altering MC4R binding kinetics.[10] This modification is considered pharmacologically significant when designing pigmentation-independent CNS studies, as reduced MC1R engagement minimizes confounding melanogenic effects in in vitro melanocyte assays.[11]
From a stability perspective, the cyclic disulfide-like lactam bridge present in both PT-141 and MT-II confers markedly greater resistance to enzymatic degradation than linear α-MSH, which is rapidly cleaved by serum proteases in ex vivo plasma stability assays (t1/2 <10 min vs. >90 min for cyclic analogs under identical conditions).[12] Researchers selecting between these compounds should consider receptor selectivity profiles, CNS penetrance requirements, and whether pigmentation-related signaling represents a confound in their specific experimental system. For MC4R-specific metabolic studies, co-administration of an MC1R-selective antagonist or use of MC1R-null (recessive yellow, e/e) mouse models has been proposed as a methodological refinement in the literature.
Conclusion
PT-141 (Bremelanotide) represents a valuable research tool for investigating melanocortin-4 receptor mechanisms and related physiological processes. Its unique cyclic structure provides enhanced stability compared to linear peptides, while its selective MC4R activation offers insights into melanocortin signaling pathways. As with all research peptides, PT-141 should be used exclusively for research purposes only, with appropriate safety protocols and regulatory compliance. Continued investigation of this peptide may contribute to advancing our understanding of melanocortin receptor biology and related physiological systems.
